CNSP · Cns Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $9.77M | $9.29M | $14.10M | $9.30M | $9.35M | $5.06M |
| SG&A | $6.21M | $5.61M | $4.77M | $5.97M | $4.68M | $4.39M |
| Total Operating Expenses | $15.99M | $14.90M | $18.87M | $15.27M | $14.03M | $9.45M |
| D&A | $3.9K | $3.3K | $4.1K | $11.8K | $13.1K | $11.1K |
| Operating Income | ($15.99M) | ($14.90M) | ($18.87M) | ($15.27M) | ($14.03M) | ($9.45M) |
| Interest Expense | $15.2K | $16.1K | $13.8K | $7.0K | $9.3K | $3.3K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($15.85M) | ($14.86M) | ($18.85M) | ($15.27M) | ($14.04M) | ($9.46M) |
| EPS - Basic | ($35.75) | ($466.44) | ($150000.00) | ($495000.00) | - | - |
| EPS - Diluted | ($35.75) | ($466.44) | ($150000.00) | ($495000.00) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.20M | $6.46M | $548.7K | $10.06M | $5.00M | $14.04M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | $3.68M | $1.52M | $946.3K |
| Current Assets | $8.10M | $8.66M | $1.59M | $12.56M | $7.48M | $15.50M |
| Total Assets | $8.62M | $8.70M | $1.70M | $13.05M | $8.76M | $15.85M |
| Current Liabilities | $4.10M | $2.52M | $6.13M | $4.92M | $2.14M | $1.91M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $4.10M | $2.52M | $6.13M | $4.92M | $2.14M | $1.91M |
| Stockholders' Equity | $4.52M | $6.18M | ($4.43M) | $8.13M | $6.62M | $13.95M |
| Retained Earnings | ($100.28M) | ($84.42M) | ($69.57M) | ($50.72M) | ($34.98M) | ($20.95M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($13.81M) | ($17.11M) | ($14.14M) | ($10.56M) | ($13.54M) | ($7.32M) |
| Investing Cash Flow | ($18.2K) | ($4.2K) | ($3.9K) | ($4.4K) | ($5.7K) | ($17.9K) |
| Financing Cash Flow | $14.57M | $23.03M | $4.64M | $15.61M | $4.51M | $14.13M |
| CapEx | $18.2K | $4.2K | $3.9K | $5.7K | - | $17.9K |
| Free Cash Flow | ($13.83M) | ($17.12M) | ($14.14M) | ($10.56M) | - | ($7.34M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.87 | 1.15 | 0.75 | 0.69 | - | 0.78 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -183.8% | -170.8% | -1108.3% | -117.0% | -160.3% | -59.7% |
| Return on equity | -350.5% | -240.5% | 425.3% | -187.8% | -212.0% | -67.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.98 | 3.43 | 0.26 | 2.55 | 3.50 | 8.13 |
| Quick ratio | 1.98 | 3.43 | 0.26 | 2.55 | 3.50 | 8.13 |
| Cash ratio | 1.76 | 2.56 | 0.09 | 2.04 | 2.34 | 7.37 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1049.7x | -924.4x | -1366.5x | -2172.6x | -1510.7x | -2896.6x |
| Equity multiplier | 1.91 | 1.41 | -0.38 | 1.60 | 1.32 | 1.14 |
| Liabilities / Assets | 0.48 | 0.29 | 3.61 | 0.38 | 0.24 | 0.12 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.5x | 4.5x | - | 7776.8x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -7.3% | 21.0% | -23.6% | -8.8% | -48.4% | -972.2% |
| Net income growth (YoY) | -6.7% | 21.2% | -23.4% | -8.8% | -48.4% | -27.9% |
| EPS growth (YoY) | 92.3% | 99.7% | 69.7% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 19.2% | -21.0% | -33.9% | - | - | -924.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -26.8% | - | - | 22.8% | -52.5% | 83.5% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CNS Pharmaceuticals against the 5 most active filers in the same SIC group.